However, considering the well-established safety profile of roflumilast, we opted to close enrollment after 10 patients were accrued, as we felt that the information obtained was sufficient to expedite the opening of a larger pivotal phase 2 trial that compares Ro+R-CHOP to R-CHOP in genetically selected subsets of DLBCL. Here, DDIT3 is linked to diffuse large B-cell lymphoma.